Allergan Seeks Quick Vraylar Turnaround After US FDA Refuses To File

Supplemental application for negative symptoms associated with schizophrenia has robust data, Datamonitor Healthcare analyst suggests, but was incomplete.

Madness

Allergan PLC is urgently seeking guidance from the US FDA to learn what prevented its supplemental new drug application (sNDA) for Vraylar (cariprazine) to treat negative symptoms associated with schizophrenia from being filed for review.

After conveying optimism about the future of its schizophrenia drug Vraylar, which has a different mechanism of action compared to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet